A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
Completed · Phase 1, Phase 2 · NCT05638802
Conditions: Systemic Lupus Erythematosus
At a glance
- Research payments reported, 2025
- $250,615
- U.S. investigators named
- 15
- Sites paid
- 18
- Planned or actual enrollment
- 26
About the trial
- Sponsor
- Daiichi Sankyo
- Tested
- DS-7011a (drug), Placebo (drug)
- Dates
- Started 2023-06-07; completion 2025-04-01
- Results posted
- Yes
Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage in multiple organs. Standard of care therapies used to treat SLE are only partially effective and have a wide range of toxicities. There is a need for more effective and safer therapies for patients with SLE.
From ClinicalTrials.gov, last updated 2026-05-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $250,615 in research payments for this study in 2025 (233 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Vishala Chindalore, M.D. Rheumatology · Anniston, AL
- Scott M. Dinehart, M.D. Mohs Surgery · Little Rock, AR
- Susan J. Lee, M.D. Rheumatology · La Jolla, CA
- Christopher G. Bunick, M.D., PH.D. Dermatology · New Haven, CT
- Juan Jose Maya Villamizar, M.D. Rheumatology · Lake Worth, FL
- Ali A. Karrar, M.D. Rheumatology · Grand Blanc, MI
- Ali Moiin, MD Dermatology · Troy, MI
- David R. Pearson, M.D. Dermatology · Minneapolis, MN
- David J. Pearson, MD Family Medicine · Cambridge, MN
- Melody Stone, MD Dermatology · Saint Joseph, MO
- Adela Rambi G. Cardones, M.D. Dermatology · Durham, NC
- Alireza Nami, M.D. Rheumatology · Charlotte, NC
- Casmiar I. Nwaigwe, MD Infectious Disease · Minot, ND
- Robert P. Lagrone, MD Rheumatology · Nashville, TN
- Dhiman Basu, MD Rheumatology · Colleyville, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $31,492
- Yale University $31,492
- Regents of the University of Minnesota $28,879
- Joint & Muscle Research Institute $25,415
- Carolinas Medical Center/behav Health, NC $24,718
- Center for Inflammatory Disease $23,899
- Trinity Health $20,584
- Arkansas Research Trials $14,841
- Medisearch Clinical Trials $10,502
- The Regents of the University of California $10,108
- Pinnacle Research Group LLC $6,656
- Revival Research Institute LLC $6,283
- Precision Comprehensive Clinical Research Solutions $6,218
- Reciomed Clinical Research Network Inc $5,987
- University of Kansas Medical Center Research Administration $3,478
- UC San Diego Health Hillcrest - Hillcrest Med Ctr, CA $32
- M Health Fairview University of Mn Medical Center, MN $16
- Aa Mrc LLC Ahmed Arif Medical Research Center $16
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.